pf-06650833
Small moleculeexperimental
Clinical trial activity
12 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2014 (NCT02224651)
Timeline
Indications
Mechanism of action
IRAK4 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- pf-06650833
- pf-06650833
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05064332 | Phase 1 | Oct 8, 2021 | Pfizer |
| NCT04933799 | Phase 2 | Jan 6, 2021 | Bronx Lebanon Hospital Center, Pfizer, St Georges University NHS Foundation Trust |
| NCT04575610 | Phase 2 | Nov 30, 2020 | Pfizer, Yale University |
| NCT04413617 | Phase 2 | May 28, 2020 | Pfizer |
| NCT04092452 | Phase 2 | Nov 11, 2019 | Pfizer |
| NCT03827668 | Phase 1 | Feb 7, 2019 | Pfizer |
| NCT03308110 | Phase 1 | Sep 12, 2017 | Pfizer |
| NCT02996500 | Phase 2 | Nov 10, 2016 | Pfizer |
| NCT02936154 | Phase 1 | Aug 1, 2016 | Pfizer |
| NCT02609139 | Phase 1 | Nov 1, 2015 | Pfizer |
| NCT02485769 | Phase 1 | Jun 1, 2015 | Pfizer |
| NCT02224651 | Phase 1 | Sep 1, 2014 | Pfizer |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 12 | 10 | 2 | 2014 |
| Bronx Lebanon Hospital Center | Academic/Hospital | 1 | 0 | 1 | 2021 |
| St Georges University NHS Foundation Trust | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Yale University | Academic/Hospital | 1 | 1 | 1 | 2020 |
4 organizations
Page 1 / 1